

Study: ENGOT-en26 /

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy

MaNGO Sites **

Prov.	City	Site	Principal Investigator	Active
CO	Como	Ospedale Sant'Anna	Monica Giordano	
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
LC	Lecco	Ospedale Manzoni	Federica Villa	
LU	Lucca	Ospedale San Luca	Editta Baldini	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	
MI	Milano	Istituto Nazionale dei Tumori	Monika Ducceschi	
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	
PI	Pisa	Ospedale Santa Chiara	Carmelo Bengala	
RM	Roma	Ospedale Umberto I	Federica Tomao	
TO	Torino	Ospedale Sant'Anna	Elisa Piovano	

* MaNGO Principal Investigator

** MaNGO sites list to be confirmed